Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000539 | 1.00 | KMT2A (0.46) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL31037753 | 1.00 | KMT2A (0.46) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL31000491 | 0.90 | CASP3 (0.50) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL12069026 | 0.90 | CASP3 (0.50) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL9995014 | 0.90 | CASP3 (0.50) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL17703894 | 0.90 | CASP3 (0.50) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL21243785 | 0.90 | CASP3 (0.50) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL31000544 | 0.85 | KMT2A (0.46) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL31000630 | 0.85 | KMT2A (0.46) | KMT2AMDM4TP53CASP3EPHX2 | |
| SCHEMBL31080829 | 0.85 | MDM4 (0.48) | KMT2AMDM4TP53CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | KMT2A 4601/4885MDM4 4764/4885TP53 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.